Jonathan Gardner
Senior Reporter | @ByJonGardner1095 articles by Jonathan Gardner
-
Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Feb. 23, 2026 -
Roche gets FDA decision date on closely watched breast cancer drug
Feb. 20, 2026 -
Ultragenyx cuts jobs as it seeks path to profit in 2027
Feb. 13, 2026 -
Nektar, continuing comeback, says eczema drug’s effects hold up in follow-up study
Feb. 10, 2026 -
Lilly buys ‘in vivo’ CAR-T maker Orna, extending streak of genetic medicine deals
Feb. 9, 2026 -
White House’s online service for drug sales debuts with limited impact on prices
Feb. 6, 2026 -
Bayer details anticipated stroke prevention data for new blood-thinner
Feb. 5, 2026 -
Novo shares tumble by double digits on grim sales outlook
Feb. 4, 2026 -
Pfizer dips on new data for obesity drug acquired in $10B deal
Feb. 3, 2026 -
Novo combination obesity shot meets goal in diabetes trial
Feb. 2, 2026 -
Amgen gives up on its once-prized eczema drug
Jan. 30, 2026 -
Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts
Jan. 28, 2026 -
Roche, trailing in obesity, showcases new data for GLP-1 shot
Jan. 27, 2026 -
Sarepta, battling slowing sales, claims Duchenne gene therapy’s impact grows with time
Jan. 26, 2026 -
Sanofi to seek approval of touted eczema drug despite mixed results
Jan. 23, 2026 -
FDA lays out new path to speed development of multiple myeloma drugs
Jan. 22, 2026 -
Corvus shares nearly triple on positive data for eczema pill
Jan. 21, 2026 -
Tecvayli tops standard drugs in early multiple myeloma, J&J says
Jan. 15, 2026 -
Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill
Jan. 14, 2026 -
Alveus launches with $160M to advance MariTide-like obesity drug
Jan. 8, 2026 -
Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs
Jan. 7, 2026 -
Alumis soars as TYK2 drug hits mark in psoriasis trials
Jan. 6, 2026 -
Zenas shares crash after top drug misses expectations in immune disease study
Jan. 5, 2026 -
Novo Nordisk’s weight loss pill approved by FDA
Dec. 23, 2025 -
Galapagos TYK2 drug hits goal in one trial, misses in another
Dec. 19, 2025